RETATRUTIDE
An experimental incretin-pathway peptide being studied for appetite regulation, weight management, and improved metabolic markers.
Laboratory and educational research purposes only.What is Retatrutide?
Retatrutide is an investigational triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. It is being developed by Eli Lilly for obesity, type 2 diabetes, and metabolic disease. Early clinical trials have shown unprecedented weight loss results, surpassing current GLP-1 agonists like semaglutide and tirzepatide.
Mechanism(s) of Action
GLP-1 receptor agonism → increases insulin secretion, reduces appetite, slows gastric emptying.
GIP receptor agonism → enhances glucose-dependent insulin release, may improve tolerability of GLP-1 effects, synergistic for weight loss.
Glucagon receptor agonism → increases energy expenditure, promotes fat oxidation, and reduces liver fat.
Triple synergy → combines appetite suppression, improved insulin sensitivity, and increased metabolic burn.
1. Significant weight loss — phase 2 data showed up to −24% body weight reduction at 48 weeks (12 mg dose).
2. Improves glycemic control — lowers HbA1c, fasting glucose, and improves insulin sensitivity.
3. Reduces visceral and liver fat — beneficial for NAFLD/NASH.
4. Cardiometabolic improvements — lowers blood pressure, improves lipid profile, reduces inflammation markers.
5. Increases energy expenditure — glucagon agonism promotes higher calorie burn.
6. Supports long-term weight maintenance — dual/triple incretin therapy sustains effects longer than single-target drugs.
7. Retains lean muscle mass — unlike many GLP-1 receptor agonists, retatrutide’s glucagon activity helps preserve muscle while cutting fat.